Due to the potential use of SRF as a therapeutic target in advanced prostate cancer and its relationship with AR, in this study, we tested the combination treatment of enzalutamide and CCG1423 in vitro and in LuCaP 35CR, a patient-derived xenograft (PDX) model of enzalutamide resistance. This evidence concerns the gene SRF and prostate carcinoma.